G
Galatea Bio
Biobank consented samples with associated clinical data from diverse populations from throughout the United States and Latin America via healthcare and biopharma partnerships
About Galatea Bio
Galatea Bio is a pioneering company in the field of genomics, focusing on precision health solutions by leveraging diverse genomic datasets. The company aims to address the underrepresentation of minority populations in genomic research, which has traditionally focused on northern European communities. By expanding the diversity of the dataset, Galatea Bio seeks to accelerate the discovery rate in genomics and narrow the gap in health outcomes for underrepresented minorities.
Read full description
Galatea Bio operates in the healthcare and biotechnology market, serving clients such as clinical labs, pharmaceutical companies, and research institutions. The business model revolves around three core offerings: GB Community, GB Discovery, and GB Health. GB Community focuses on biobanking with an emphasis on diversity, starting with the Biobank of the Americas. GB Discovery leverages the data from GB Community to develop new algorithms and pharmaceutical targets. GB Health aims to build a clinical lab that delivers actionable results to partners in the clinic and pharma sectors.
The company generates revenue through partnerships, research collaborations, and providing genomic data and insights to its clients. By focusing on the unique genetic makeup of minorities, Galatea Bio aims to uncover novel genetic associations that can lead to the development of new drugs and therapies.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Hialeah, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
Latest news
Press, funding announcements and product moves mentioning Galatea Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2025 | $25M | $100M | Founder Collective · Digitalis Ventures · HBM Genomics · F-Prime | ↗ |
| SERIES A✓Equity / VC | Nov 2022 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for Galatea Bio is 2.4K monthly website visits, up 60% over the last three months. Galatea Bio's team declined 11.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
F-Prime
Digitalis Ventures
Series A7 investors entered at this stage
Founder Collective
HBM Genomics
AME Cloud Ventures
CEI Ventures
Alexandria Venture Investments
Stanford University
Helios Digital Ventures
Other known investors4 additional known investors
Chas Pulido
Edward Lando
Function
LifeX Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Galatea Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Galatea Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.